TRADD

Across TCGA pan-cancer cohorts, TRADD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRADD data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TRADD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRADD expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where TRADD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.879	0.286	.006	36	view →
LSCC	DFS	Median	II,III,IV	0.506	0.887	.001	36	view →
CCRCC	DFS	Median	All	0.580	0.882	.001	23	view →
GBM	DFS	Tertile	All	0.616	0.858	.005	16	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRADD–HNSC (DFS)

Open the HNSC breakdown →